Clinical Trial Update: Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in treatment-naïve distant metastatic melanoma with use of C11-AMT PET imaging at baseline as a biomarker; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2022-07-14